What Is Retatrutide?
Retatrutide (LY3437943) is a synthetic peptide developed by Eli Lilly with agonist activity at GIP, GLP-1 and glucagon receptors. The 2023 phase 2 study in the New England Journal of Medicine reported mean body-weight reductions of 17.5% at 24 weeks and 24.2% at 48 weeks in the highest dose group. These are trial findings, not outcomes established for catalogue products.
For mechanism of action and clinical-trial context, see our Retatrutide Research Overview. Published clinical research does not establish equivalence of a commercial research sample to the trial material.
For supplier evaluation and interpreting batch documentation, read our Retatrutide research supplier guide.
This page focuses on procurement. The research overview covers the science. For research use only.
Retatrutide Products
Two concentrations available, supplied in boxes of 10 research-grade vials.
Why Researchers Choose Eternal Peptides Wholesale
Published Batch Reports
Review the published reports for the selected product and batch. Only the tests and results shown on those reports apply; do not assume additional methods or testing were performed.
Australian-Owned
Not an overseas supplier behind an Australian domain. Eternal Peptides Wholesale is an Australian business. Contact us about supplier and invoicing documentation before ordering.
COAs Available Before Purchase
Every COA includes the Janoshik report number for independent verification at janoshik.com. You can review the testing data before placing an order — not only after.
Wholesale Box Pricing
Products are supplied in box quantities (10 vials per box). No per-vial markups. Pricing structure designed for research procurement budgets, not single-use retail.
About Janoshik Analytical Testing
Janoshik Analytical is an accredited third-party laboratory used widely by research peptide suppliers. Unlike in-house testing, third-party verification through Janoshik provides independent confirmation of identity and purity.
Each COA includes a unique report number. You can verify any COA independently by looking up the report number at janoshik.com. This removes any possibility of falsified documentation — if the COA is real, the verification check will pass.
Review the published reports for the selected product and batch. Only the tests and results shown on those reports apply; do not assume additional methods or testing were performed.
Third-Party Lab Reports
Current batch test results for RT10 and RT20, independently verified by Janoshik Analytical.
RT10 (10mg)
RT20 (20mg)
Regulatory Context for GLP-1 Class Compounds in Australia
Eternal Peptides Wholesale supplies catalogue products for qualified laboratory research only. Research-use wording does not remove applicable Australian legal requirements. Products are not supplied for human therapeutic use or compounding for human administration. Customers should check the current requirements for their specific research context.
Frequently Asked Questions
Where can I buy Retatrutide in Australia? +
Eternal Peptides Wholesale is an Australian-based online distributor supplying Retatrutide for research purposes. RT10 (10mg, box of 10) is $544.50 and RT20 (20mg, box of 10) is $891.00. Check the product page for available batch reports. Free shipping. For research use only.
What is the difference between RT10 and RT20? +
RT10 contains 10mg of Retatrutide per vial (box of 10 vials, $544.50). RT20 contains 20mg of Retatrutide per vial (box of 10 vials, $891.00). Both are supplied as boxes of 10 vials. Concentration selection depends on your research protocol. Both are independently verified by Janoshik Analytical with batch-specific COAs on each product page. For research use only.
How is the quality of Retatrutide verified? +
Review the published reports for the selected product and batch. Only the tests and results shown on those reports apply; do not assume additional methods or testing were performed.
What is Retatrutide's mechanism of action? +
Retatrutide has agonist activity at GIP, GLP-1 and glucagon receptors. See the Retatrutide Research Overview for receptor mechanisms and cited clinical-trial findings. For research use only.
Is Retatrutide approved for human use in Australia? +
No. Retatrutide is currently in Phase 3 clinical development and is not approved by the TGA for therapeutic use in Australia. Eternal Peptides Wholesale supplies Retatrutide for qualified laboratory research use only. It is not for human therapeutic use or consumption. GLP-1 class compounds have been subject to increased TGA regulatory attention since October 2024. Customers should seek independent legal and compliance advice regarding their specific research context.
How long does shipping take? +
Orders are typically processed within 1–5 business days. Estimated delivery is 5–7 business days after dispatch, depending on destination and customs clearance. Dispatch origin can vary, including offshore fulfilment; Australian business ownership does not guarantee domestic stock or customs-free delivery. Consult our Shipping Policy for current processing and delivery estimates. Certificates of Analysis are included with every order. Contact us before ordering if your protocol has specific temperature or logistics requirements.
Related Research Resources
Related research articles
- MOTS-c: why an exercise study is not a trial of a peptide injection
- Peptides in Australia: what to check before trusting a buying claim
- Avoiding Counterfeit Peptides: Verify COAs and Peptide Content
- In Vitro Studies Using Retatrutide: A Researcher’s Guide
- Retatrutide Mechanism of Action: What Studies Show